Article info
PDFAdverse drug reactions
‘Triple therapy’ (elexacaftor, tezacaftor, ivacaftor) skin rash in patients with cystic fibrosis
- Correspondence to Dr May Khei Hu, Department of Respiratory Medicine, Aberdeen Royal Infirmary, Aberdeen AB25 2ZN, UK; maykhei.hu{at}nhs.net
Citation
‘Triple therapy’ (elexacaftor, tezacaftor, ivacaftor) skin rash in patients with cystic fibrosis
Publication history
- Received October 20, 2020
- Revised November 25, 2020
- Accepted November 29, 2020
- First published December 11, 2020.
Online issue publication
January 20, 2022
Article Versions
- Previous version (11 December 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.